Viking Therapeutics ratios data for the quarter ended Jun 2026. These financial ratios cover 48 quarters of results from Mar 2014 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Mar2014 | Dec2014 | Mar2015 | Jun2015 | Sep2015 | Dec2015 | Mar2016 | Jun2016 | Sep2016 | Dec2016 | Mar2017 | Jun2017 | Sep2017 | Dec2017 | Mar2018 | Jun2018 | Sep2018 | Dec2018 | Mar2019 | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Efficiency | ||||||||||||||||||||||||||||||||||||||||||||||||
| Assets AverageAssets Avg. | 231.16M | 217.57M | 202.84M | 188.27M | 174.10M | 167.61M | 159.71M | 275.79M | 391.68M | 375.58M | 668.00M | 957.18M | 942.36M | 923.10M | 887.66M | 847.42M | 783.63M | 727.57M | 661.99M | 565.07M | ||||||||||||||||||||||||||||
| Invested CapitalInvested Cap. | ||||||||||||||||||||||||||||||||||||||||||||||||
| Leverage & Solvency | ||||||||||||||||||||||||||||||||||||||||||||||||
| Interest Coverage RatioInterest Cover | ||||||||||||||||||||||||||||||||||||||||||||||||
| Debt Ratio | ||||||||||||||||||||||||||||||||||||||||||||||||
| Times Interest Earned | ||||||||||||||||||||||||||||||||||||||||||||||||
| Valuation | ||||||||||||||||||||||||||||||||||||||||||||||||
| Price to EarningsP/E | -37.00 | -29.14 | -13.54 | -12.75 | -13.25 | -37.63 | -67.72 | -84.48 | -49.14 | -75.80 | -330.75 | -264.16 | -281.92 | -126.85 | -59.46 | -45.42 | -32.55 | -25.61 | -23.82 | -35.54 | ||||||||||||||||||||||||||||
| Price to BookP/B | 2.31 | 1.78 | 1.27 | 1.34 | 1.38 | 5.06 | 9.85 | 4.20 | 3.01 | 5.35 | 9.68 | 6.38 | 7.74 | 5.10 | 3.20 | 3.74 | 4.14 | 6.32 | 7.51 | 11.14 | ||||||||||||||||||||||||||||
| Enterprise Value | 275.18M | 157.84M | -118.93M | -83.75M | 53.57M | 580.13M | 1,185.00M | 1,228.55M | 731.08M | 1,501.04M | 8,075.79M | 4,931.04M | 6,124.50M | 3,587.11M | 1,859.92M | 2,169.01M | 2,240.54M | 3,332.68M | 3,168.23M | 4,048.97M | ||||||||||||||||||||||||||||
| EV to EBIT | -20.53 | -12.62 | 7.32 | 4.75 | -3.31 | -28.60 | -57.70 | -51.75 | -26.81 | -51.26 | -237.01 | -144.80 | -167.54 | -77.58 | -33.53 | -29.09 | -22.73 | -20.23 | -19.30 | -30.54 | ||||||||||||||||||||||||||||
| EV to EBITDA | -20.53 | -12.62 | 7.32 | 4.75 | -3.31 | -28.60 | -57.70 | -51.75 | -26.81 | -51.26 | -237.01 | -144.80 | -167.54 | -77.58 | -33.53 | -29.09 | -22.73 | -20.23 | -19.30 | -30.54 | ||||||||||||||||||||||||||||
| Market Capitalization | 491.32M | 359.94M | 232.12M | 221.63M | 208.59M | 735.62M | 1,320.66M | 1,621.47M | 1,107.32M | 1,863.12M | 9,038.77M | 5,873.31M | 7,054.94M | 4,489.72M | 2,711.77M | 2,976.74M | 2,955.11M | 4,038.42M | 3,771.19M | 4,550.63M | ||||||||||||||||||||||||||||
| Price to FCFP/FCF | -44.97 | -29.15 | -22.04 | -16.49 | -15.45 | -67.33 | -53.59 | -141.80 | -56.33 | -105.62 | -0.00M | -205.99 | -321.23 | -143.99 | -51.82 | -63.25 | -31.44 | -47.35 | -33.09 | -36.36 | ||||||||||||||||||||||||||||
| EV to FCF | -25.19 | -12.78 | 11.29 | 6.23 | -3.97 | -53.10 | -48.09 | -107.44 | -37.19 | -85.09 | -0.00M | -172.94 | -278.87 | -115.04 | -35.54 | -46.09 | -23.83 | -39.07 | -27.80 | -32.35 | ||||||||||||||||||||||||||||
| EV to CFO | -25.19 | -12.78 | 11.29 | 6.23 | -3.97 | -53.10 | -48.09 | -107.44 | -37.19 | -85.09 | -0.00M | -172.94 | -278.87 | -115.04 | -35.54 | -46.09 | -23.83 | -39.07 | -27.80 | -32.35 | ||||||||||||||||||||||||||||
| Return Ratios | ||||||||||||||||||||||||||||||||||||||||||||||||
| Return on Capital Employed [ROCE]ROCE | -24.77% | -26.67% | -30.12% | -34.48% | -39.11% | -48.30% | -51.82% | -30.79% | -24.27% | -28.29% | -18.00% | -13.38% | -14.61% | -16.85% | -19.85% | -26.10% | -36.28% | -60.43% | -90.34% | -122.97% | ||||||||||||||||||||||||||||
| Return on Assets [ROA]ROA | -23.18% | -25.27% | -28.66% | -31.95% | -35.96% | -41.65% | -45.19% | -26.83% | -20.62% | -22.85% | -14.02% | -10.10% | -10.52% | -11.91% | -14.45% | -20.25% | -30.29% | -49.43% | -71.35% | -94.66% |
Pull Viking Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=VKTX&statement=Ratios&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "VKTX", "statement": "Ratios", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=VKTX&statement=Ratios&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();